Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 24;17(13):2120.
doi: 10.3390/cancers17132120.

Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review

Katerina Zarampouka  1 , Christos Tsiantas  2 , Maria Athanasia Stavropoulou  2 , Konstantinos Efthymiadis  1 , Paschalis Theotokis  2 , Sofia Gargani  2 , Eleni Vrettou  2 , Triantafyllia Koletsa  1 , Maria Eleni Manthou  2 , Soultana Meditskou  2
Affiliations
Review

Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review

Katerina Zarampouka et al. Cancers (Basel). .

Abstract

Background/Objectives: Gastric cancer (GC) is the fifth leading cause of cancer-related mortality. CLDN18.2 is a tight junction protein, expressed in gastric mucosa and is considered as a novel therapeutic target. Even though CLDN18.2 is associated with various components of the tumor microenvironment and the relation with clinical histopathological parameters has been widely studied, there is no sufficient data on the associations of CLDN18.2 expression and the components of the tumor microenvironment. This systematic review aims to gather and present all available data about the correlation of CLDN 18.2 expression and the tumor microenvironment. Methods: The research questions were systematically formulated using the PICO model to ensure clarity and precision, and the PRISMA flow diagram was constructed to detail the study selection process. Results: Sixteen original articles were retrieved. The major finding of this study was the positive correlation between CLDN18.2 expression and CD8+ T cells, neutrophils and cancer-associated fibroblasts. No correlation was found between CLDN18.2 expression and Tregs and B cells. For the remaining components of the microenvironment, there are contradictory data about their correlation with the expression of CLDN18.2. Conclusions: The tumor microenvironment plays a critical role in cancer progression and needs to be studied more thoroughly.

Keywords: CLDN18.2; gastric cancer; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram [53].
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer. 2021;149:778–789. doi: 10.1002/ijc.33588. - DOI - PubMed
    1. Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K., Meyer L., Gress D.M., Byrd D.R., Winchester D.P. The Eighth Edition AJCC Cancer Staging Manual: Continuing to Build a Bridge from a Population-based to a More “Personalized” Approach to Cancer Staging. CA Cancer J. Clin. 2017;67:93–99. doi: 10.3322/caac.21388. - DOI - PubMed
    1. Song H., Zhu J., Lu D. Molecular-Targeted First-Line Therapy for Advanced Gastric Cancer. Cochrane Database Syst. Rev. 2016;2016:CD011461. doi: 10.1002/14651858.CD011461.pub2. - DOI - PMC - PubMed
    1. Zaanan A., Bouche O., De La Fouchardiere C., Samalin-Scalzi E., Le Malicot K., Pernot S., Artru P., Lebrun V.L., Aldabbagh K., Akouz F.K., et al. LBA77 5-Fluorouracil and Oxaliplatin with or without Docetaxel in the First-Line Treatment of HER2 Negative Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma (GASTFOX-PRODIGE 51): A Randomized Phase III Trial Sponsored by the FFCD. Ann. Oncol. 2023;34:S1318. doi: 10.1016/j.annonc.2023.10.078. - DOI

LinkOut - more resources